Clinical trial · Interventional
Multimodalitic Imaging in the N-stage of Lung Cancer
A Prospective Study of the Predictive and Prognostic Value of Multimodalitic Imaging in the N-stage of Lung Cancer
NCT05840094CI-TRIAL-00066127unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to evaluate the diagnostic efficacy and differences between 18F-FDG PET/CT and MR STIR sequences combined with EBUS-TBNA, 18F-FDG PET/CT combined with EBUS-TBNA, and MR STIR sequences combined with EBUS-TBNA - three types of multimodal imaging for assessing NSCLC N-stage, in order to select the best assessment protocol to guide treatment decisions and prognostic assessments.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasm of Lung | Lung Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18F-FDG | Drug | — | UNRESOLVED |
| EBUS-TBNA | Procedure | — | UNRESOLVED |
| MR STIR | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- PET/CT+MR+EBUS
- description
- Subjects will receive 18F-FDG PET/CT and MR STIR sequence combined with EBUS-TBNA, to diagnose the N-stage of NSCLC
- interventionNames
- Drug: 18F-FDG
- Device: MR STIR
- Procedure: EBUS-TBNA
- type
- EXPERIMENTAL
- label
- PET/CT+EBUS
- description
- Subjects will receive 18F-FDG PET/CT and EBUS-TBNA, to diagnose the N-stage of NSCLC
- interventionNames
- Drug: 18F-FDG
- Procedure: EBUS-TBNA
- type
- EXPERIMENTAL
- label
- MR+EBUS
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Biopsy pathologically confirmed NSCLC, or clinically highly suspicious NSCLC (assessed as highly suspicious by the MDT team of this study); * N1, N2, or N3 confined to the mediastinum and hilum, as assessed by imaging; * Proposed systematic lymph node dissection without any treatment; * Appropriate laboratory tests (serum tumor markers); * All examination intervals ≤ 4 weeks; * KPS score ≥ 50 (ECOG/WHO equivalent); * Aged \> 18 years; 8. Patients can fully understand and voluntarily participate in this trial and sign the informed consent; the examination can be completed independently. Exclusion Criteria: * Contraindication to EBUS-TBNA operation; * Presence or history of other malignancies within 10 years; * Inability to understand the examination procedure or to cooperate.
References
Publications (0)
Data not yet available
No reference posted for this study.